Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.
Antiplatelet therapy
Coronary artery disease
Genotype
Myocardial infarction
Percutaneous coronary intervention
Journal
Cardiovascular intervention and therapeutics
ISSN: 1868-4297
Titre abrégé: Cardiovasc Interv Ther
Pays: Japan
ID NLM: 101522043
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
27
08
2020
accepted:
07
10
2020
pubmed:
14
11
2020
medline:
26
11
2021
entrez:
13
11
2020
Statut:
ppublish
Résumé
The ultra-short dual antiplatelet therapy (DAPT) followed by P2Y
Identifiants
pubmed: 33184726
doi: 10.1007/s12928-020-00719-6
pii: 10.1007/s12928-020-00719-6
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Clopidogrel
A74586SNO7
CYP2C19 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP2C19
EC 1.14.14.1
Banques de données
ClinicalTrials.gov
['NCT02619760']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-415Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020. Japanese Association of Cardiovascular Intervention and Therapeutics.
Références
Valgimigli M, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, et al. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ. 2014;349:g6427.
doi: 10.1136/bmj.g6427
Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–47.
doi: 10.1056/NEJMoa1503943
Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020;382:1208–18.
doi: 10.1056/NEJMoa1910021
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940–9.
doi: 10.1016/S0140-6736(18)31858-0
Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414–27.
doi: 10.1001/jama.2019.8145
Hahn J-Y, Song YB, Oh J-H, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321:2428–37.
doi: 10.1001/jama.2019.8146
Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032–42.
doi: 10.1056/NEJMoa1908419
Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–13.
doi: 10.1161/01.CIR.0000072771.11429.83
Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309–17.
doi: 10.1016/S0140-6736(08)61845-0
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.
doi: 10.1056/NEJMoa0809171
Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.
doi: 10.1056/NEJMoa0808227
Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, et al. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J. 2009;73:1498–503.
doi: 10.1253/circj.CJ-09-0019
Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. 2010;50:929–40.
doi: 10.1177/0091270009355161
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704–14.
doi: 10.1056/NEJMoa1008410
Palmerini T, Calabrò P, Piscione F, De Servi S, Cattaneo M, Maffeo D, et al. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. JACC Cardiovasc Interv. 2014;7:1117–27.
doi: 10.1016/j.jcin.2014.04.020
Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588.
doi: 10.1136/bmj.d4588
Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60.
doi: 10.1093/eurheartj/ehx419
Park D-W, Kwon O, Jang J-S, Yun S-C, Park H, Kang D-Y, TICAKOREA Investigators, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation. 2019;140:1865–77.
doi: 10.1161/CIRCULATIONAHA.119.041766
Goto S, Huang C-H, Park S-J, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome—randomized, double-blind, phase III PHILO study. Circ J. 2015;79:2452–60.
doi: 10.1253/circj.CJ-15-0112
Akita K, Inohara T, Yamaji K, Kohsaka S, Numasawa Y, Ishii H, et al. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62,737 patients with acute coronary syndromes: a nationwide registry study in Japan. Eur Heart J Cardiovasc Pharmacother. 2019. https://doi.org/10.1093/ehjcvp/pvz056 .
doi: 10.1093/ehjcvp/pvz056
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115:2344–51.
doi: 10.1161/CIRCULATIONAHA.106.685313
Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11.
doi: 10.1016/0735-1097(88)90158-1
Sianos G, Morel M-A, Kappetein AP, Morice M-C, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219–27.
pubmed: 19758907
Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–9.
doi: 10.1056/NEJM199604253341702
Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–71.
doi: 10.1056/NEJM199812033392303
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
doi: 10.1056/NEJMoa010746
Sibbing D, Aradi D, Alexopoulos D, ten Berg J, Bhatt DL, Bonello L, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12:1521–37.
doi: 10.1016/j.jcin.2019.03.034
Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van Hof AWJ, van Harst P, Ten Berg JM, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621–31.
doi: 10.1056/NEJMoa1907096
Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324:761–71.
doi: 10.1001/jama.2020.12443